According to Sunovion Pharmaceuticals, Zetonna ciclesonide nasal aerosol for the treatment of perennial and seasonal allergic rhinitis is now available throughout the US. The company announced in May that it would launch the product by this fall. Sunovion also markets Omnaris ciclesonide nasal spray for the treatment of allergic rhinitis and Alvesco ciclesonide inhalation aerosol for the treatment of asthma.
Sunovion Executive VP and Chief Commercial Officer Richard Russell commented, “Zetonna joins Omnaris ciclesonide nasal spray as the newest addition in Sunovion’s ciclesonide franchise. These treatments offer different experiences for patients, as Omnaris is an aqueous, once-daily, two spray per nostril option for SAR patients 6 and older and PAR patients 12 and older. We are proud to be the only company to provide patients with the option of a dry aerosol or aqueous treatment, as well as a best-in-class co-pay program that allows qualified patients to pay as little as $17 a month for either Zetonna or Omnaris.”
Read the Sunovion press release.
